<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33905493</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial.</ArticleTitle><Pagination><StartPage>2635</StartPage><EndPage>2647</EndPage><MedlinePgn>2635-2647</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awab167</ELocationID><Abstract><AbstractText>Strong evidence suggests that endoplasmic reticulum stress plays a critical role in the pathogenesis of amyotrophic lateral sclerosis (ALS) through altered regulation of proteostasis. Robust preclinical findings demonstrated that guanabenz selectively inhibits endoplasmic reticulum stress-induced eIF2&#x3b1;-phosphatase, allowing misfolded protein clearance, reduces neuronal death and prolongs survival in in vitro and in vivo models. However, its safety and efficacy in patients with ALS are unknown. To address these issues, we conducted a multicentre, randomized, double-blind trial with a futility design. Patients with ALS who had displayed an onset of symptoms within the previous 18&#x2009;months were randomly assigned in a 1:1:1:1 ratio to receive 64&#x2009;mg, 32&#x2009;mg or 16&#x2009;mg of guanabenz or placebo daily for 6&#x2009;months as an add-on therapy to riluzole. The purpose of the placebo group blinding was to determine safety but not efficacy. The primary outcome was the proportion of patients progressing to higher stages of disease within 6&#x2009;months as measured using the ALS Milano-Torino staging system, compared with a historical cohort of 200 patients with ALS. The secondary outcomes were the rate of decline in the total revised ALS functional rating scale score, slow vital capacity change, time to death, tracheotomy or permanent ventilation and serum light neurofilament level at 6&#x2009;months. The primary assessment of efficacy was performed using intention-to-treat analysis. The treatment arms using 64&#x2009;mg and 32&#x2009;mg guanabenz, both alone and combined, reached the primary hypothesis of non-futility, with the proportions of patients who progressed to higher stages of disease at 6&#x2009;months being significantly lower than that expected under the hypothesis of non-futility and a significantly lower difference in the median rate of change in the total revised ALS functional rating scale score. This effect was driven by patients with bulbar onset, none of whom (0/18) progressed to a higher stage of disease at 6&#x2009;months compared with those on 16&#x2009;mg guanabenz (4/8; 50%), the historical cohort alone (21/49; 43%; P&#x2009;=&#x2009;0.001) or plus placebo (25/60; 42%; P&#x2009;=&#x2009;0.001). The proportion of patients who experienced at least one adverse event was higher in any guanabenz arm than in the placebo arm, with higher dosing arms having a significantly higher proportion of drug-related side effects and the 64&#x2009;mg arm a significantly higher drop-out rate. The number of serious adverse events did not significantly differ between the guanabenz arms and the placebo. Our findings indicate that a larger trial with a molecule targeting the unfolded protein response pathway without the alpha-2 adrenergic related side-effect profile of guanabenz is warranted.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dalla Bella</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>3rd Neurology Unit and Motor Neuron Disease Centre, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan 20133, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bersano</LastName><ForeName>Enrica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>3rd Neurology Unit and Motor Neuron Disease Centre, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan 20133, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonini</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>NESMOS Department, Neuromuscolar Disease Unit, Sant'Andrea Hospital and University of Rome "Sapienza", Rome 00189, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borghero</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neurologic Unit, Monserrato University Hospital, Cagliari 09042, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capasso</LastName><ForeName>Margherita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurologic Clinic, SS. Annunziata Hospital, Chieti 66100, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caponnetto</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>San Martino Polyclinic Hospital, Genoa 16132, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Centre "Rita Levi Montalcini", Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corbo</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurorehabilitaton, Casa Cura Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filosto</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2852-7512</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili Brescia and NeMO-Brescia Clinical Centre for Neuromuscular Diseases, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannini</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgery Sciences and Neurosciences, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spataro</LastName><ForeName>Rossella</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8910-3131</Identifier><AffiliationInfo><Affiliation>ALS Research Centre, BioNeC, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4788-1875</Identifier><AffiliationInfo><Affiliation>NEuroMuscular Omnicentre of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandrioli</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messina</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit of Neurology and Neuromuscular Disorders, Department of Clinical and Experimental Medicine and University of Messina, AOU Policlinico "G. Martino", Messina, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NEuroMuscular Omnicentre of Messina, University Hospital "G. Martino", Messina, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monsurr&#xf2;</LastName><ForeName>Maria Rosaria</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>"Luigi Vanvitelli" Campania University Naples, Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>ICS Maugeri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riva</LastName><ForeName>Nilo</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0513-9517</Identifier><AffiliationInfo><Affiliation>Department of Neurology IRCCS "San Raffaele" Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzi</LastName><ForeName>Romana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Neuro-Motor Diseases, Azienda Unit&#xe0; Sanitaria Locale, IRCCS of Reggio Emilia, Reggio Emilia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siciliano</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, Neurology Unit, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology-Stroke Unit and Laboratory of Neuroscience, Istituto Auxologico Italiano IRCCS, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari" Centre and Centre for Neurotechnology and Brain Therapeutics, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simone</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, University of Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorar&#xf9;</LastName><ForeName>Gianni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tugnoli</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Rehabilitation, Division of Neurology, University Hospital of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verriello</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neurology Unit, S. Maria della Misericordia University Hospital, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volanti</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Intensive Neurorehabilitation Unit, ICS Maugeri IRCCS, Mistretta, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furlan</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Neuroimmunology Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nolan</LastName><ForeName>John M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-1234-0304</Identifier><AffiliationInfo><Affiliation>Drew University, Caspersen School of Graduate Studies, Madison, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abgueguen</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>InFlectis BioScience, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tramacere</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Scientific Directorate, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauria</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-9773-020X</Identifier><AffiliationInfo><Affiliation>3rd Neurology Unit and Motor Neuron Disease Centre, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan 20133, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058647">Adrenergic alpha-2 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>GGD30112WC</RegistryNumber><NameOfSubstance UI="D006143">Guanabenz</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058647" MajorTopicYN="N">Adrenergic alpha-2 Receptor Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006143" MajorTopicYN="N">Guanabenz</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056811" MajorTopicYN="N">Unfolded Protein Response</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">guanabenz</Keyword><Keyword MajorTopicYN="N">unfolded protein response</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>27</Day><Hour>17</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33905493</ArticleId><ArticleId IdType="pmc">PMC8557337</ArticleId><ArticleId IdType="doi">10.1093/brain/awab167</ArticleId><ArticleId IdType="pii">6255742</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ito H. Basophilic inclusions and neuronal intermediate filament inclusions in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Neuropathology. 2014;34(6):589&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">24673472</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbour D, Vande Velde C, Robitaille R.. New perspectives on amyotrophic lateral sclerosis: The role of glial cells at the neuromuscular junction. J Physiol. 2017;595(3):647&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5285712</ArticleId><ArticleId IdType="pubmed">27633977</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Rothstein JD.. Glial cells in amyotrophic lateral sclerosis. Exp Neurol. 2014;262(Pt B):111&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4241182</ArticleId><ArticleId IdType="pubmed">24859452</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza PV, Pinto WB, Rezende FMF, Oliveira AS.. Far beyond the motor neuron: The role of glial cells in amyotrophic lateral sclerosis. Arq Neuro-Psiquiatr. 2016;74(10):849&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">27759812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SH, Li Y, Fukaya M, et al.Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci. 2013;16(5):571&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637847</ArticleId><ArticleId IdType="pubmed">23542689</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH Jr, Al-Chalabi A.. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(16):1602.</Citation><ArticleIdList><ArticleId IdType="pubmed">29045202</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter P, Ron D.. The unfolded protein response: From stress pathway to homeostatic regulation. Science. 2011;334(6059):1081&#x2013;1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">22116877</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrivastava AN, Aperia A, Melki R, Triller A.. Physico-pathologic mechanisms involved in neurodegeneration: misfolded protein-plasma membrane interactions. Neuron. 2017;95(1):33&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">28683268</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC.. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013;501(7465):45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Munch C, Bertolotti A.. Self-propagation and transmission of misfolded mutant SOD1: Prion or prion-like phenomenon? Cell Cycle. 2011;10(11):1711.</Citation><ArticleIdList><ArticleId IdType="pubmed">21471733</ArticleId></ArticleIdList></Reference><Reference><Citation>Munch C, O'Brien J, Bertolotti A.. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci U S A. 2011;108(9):3548&#x2013;3553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048161</ArticleId><ArticleId IdType="pubmed">21321227</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Cleveland DW.. The seeds of neurodegeneration: Prion-like spreading in ALS. Cell. 2011;147(3):498&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220614</ArticleId><ArticleId IdType="pubmed">22036560</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Kim HJ.. Prion-like mechanism in amyotrophic lateral sclerosis: Are protein aggregates the key? Exp Neurobiol. 2015;24(1):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4363329</ArticleId><ArticleId IdType="pubmed">25792864</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekura K, Suzuki H, Aiso S, Matsuoka M.. ER stress and unfolded protein response in amyotrophic lateral sclerosis. Mol Neurobiol. 2009;39(2):81&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">19184563</ArticleId></ArticleIdList></Reference><Reference><Citation>Maharjan N, Saxena S.. ER strikes again: Proteostasis dysfunction in ALS. EMBO J. 2016;35(8):798&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4972132</ArticleId><ArticleId IdType="pubmed">26968985</ArticleId></ArticleIdList></Reference><Reference><Citation>Parakh S, Atkin JD.. Protein folding alterations in amyotrophic lateral sclerosis. Brain Res. 2016;1648(Pt B):633&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">27064076</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Popko B, Roos RP.. The unfolded protein response in familial amyotrophic lateral sclerosis. Hum Mol Genet. 2011;20(5):1008&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3033190</ArticleId><ArticleId IdType="pubmed">21159797</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, Atkin JD.. Stress signaling from the endoplasmic reticulum: A central player in the pathogenesis of amyotrophic lateral sclerosis. IUBMB Life. 2011;63(9):754&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">21834058</ArticleId></ArticleIdList></Reference><Reference><Citation>Vats A, Gourie-Devi M, Ahuja K, et al.Expression analysis of protein homeostasis pathways in the peripheral blood mononuclear cells of sporadic amyotrophic lateral sclerosis patients. J Neurol Sci. 2018;387:85&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">29571878</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkin JD, Farg MA, Walker AK, McLean C, Tomas D, Horne MK.. Endoplasmic reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic lateral sclerosis. Neurobiol Dis. 2008;30(3):400&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">18440237</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruegsegger C, Saxena S.. Proteostasis impairment in ALS. Brain Res. 2016;1648(Pt B):571&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">27033833</ArticleId></ArticleIdList></Reference><Reference><Citation>Yerbury JJ, Ooi L, Dillin A, et al.Walking the tightrope: Proteostasis and neurodegenerative disease. J Neurochem. May 2016;137(4):489&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">26872075</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JH, Walter P, Yen TS.. Endoplasmic reticulum stress in disease pathogenesis. Annu Rev Pathol. 2008;3:399&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653419</ArticleId><ArticleId IdType="pubmed">18039139</ArticleId></ArticleIdList></Reference><Reference><Citation>Ron D, Harding HP.. Protein-folding homeostasis in the endoplasmic reticulum and nutritional regulation. Cold Spring Harb Perspect Biol. 2012;4(12).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3504434</ArticleId><ArticleId IdType="pubmed">23209157</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva EV, Ayala V, Jov&#xe9; M, et al.Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain. 2007;130(Pt 12):3111&#x2013;3123.</Citation><ArticleIdList><ArticleId IdType="pubmed">17716997</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S. Endoplasmic reticulum stress in motor neurons of the spinal cord in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2010;69(4):346&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">20448480</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa-Mattioli M, Walter P.. The integrated stress response: From mechanism to disease. Science. 2020;368(6489):eaat5314.</Citation><ArticleIdList><ArticleId IdType="pubmed">32327570</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsaytler P, Harding HP, Ron D, Bertolotti A.. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science. 2011;332(6025):91&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">21385720</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccaro A, Patten SA, Aggad D, et al.Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. Neurobiol Dis. 2013;55:64&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">23567652</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbezier N, Chartier A, Bidet Y, et al.Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy. EMBO Mol Med. 2011;3(1):35&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044817</ArticleId><ArticleId IdType="pubmed">21204267</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Popko B, Tixier E, Roos RP.. Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis. Neurobiol Dis. 2014;71:317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4179984</ArticleId><ArticleId IdType="pubmed">25134731</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang HQ, Ren M, Jiang HZ, et al.Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neuroscience. 2014;277:132&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">24699224</ArticleId></ArticleIdList></Reference><Reference><Citation>Das I, Krzyzosiak A, Schneider K, et al.Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science. 2015;348(6231):239&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4490275</ArticleId><ArticleId IdType="pubmed">25859045</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalla Bella E, Tramacere I, Antonini G, et al.Protein misfolding, amyotrophic lateral sclerosis and guanabenz: Protocol for a phase II RCT with futility design (ProMISe trial). BMJ Open. 2017;7(8):e015434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5724081</ArticleId><ArticleId IdType="pubmed">28801400</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron D. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp R. The Hamilton Rating Scale for Depression. Occup Med (Lond). 2015;65(4):340-</Citation><ArticleIdList><ArticleId IdType="pubmed">25972613</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Hammond ER, Mora G, Bonito V, Filippini G.. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):38&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">24336810</ArticleId></ArticleIdList></Reference><Reference><Citation>Tramacere I, Dalla Bella E, Chio A, et al.The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(11):1180&#x2013;1185.</Citation><ArticleIdList><ArticleId IdType="pubmed">25886781</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauria G, Dalla Bella E, Antonini G, et al.; EPOS Trial Study Group. Erythropoietin in amyotrophic lateral sclerosis: A multicentre, randomised, double blind, placebo controlled, phase III study. J Neurol Neurosurg Psychiatry. 2015;86(8):879&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4515982</ArticleId><ArticleId IdType="pubmed">25595151</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey JH, et al.Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: A retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17(5):416&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Moglia C, Lizio A, et al.; and EDARAVALS Study Group. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J Neurol. 2020;267(11):3258&#x2013;3267.</Citation><ArticleIdList><ArticleId IdType="pubmed">32556567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al.Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Berry J, Shui A, et al.The PRO-ACT database: Design, initial analyses, and predictive features. Neurology. 2014;83(19):1719&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Katz J, Moore DH, et al.Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(3):259&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">19961263</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, Wicks P, Vaughan T, et al.Lunasin does not slow ALS progression: Results of an open-label, single-center, hybrid-virtual 12-month trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3-4):285&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663902</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD, Hertzberg VS, Boulis NM, et al.Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials. Neurology. 2016;87(4):392&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977116</ArticleId><ArticleId IdType="pubmed">27358335</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Brown MB, Glass JD, et al.Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Ann Clin Transl Neurol. 2018;5(6):730&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5989736</ArticleId><ArticleId IdType="pubmed">29928656</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine TD, Miller RG, Bradley WG, et al.Phase I clinical trial of safety of L-serine for ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(1-2):107&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">27589995</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier A, Deigendesch N, M&#xfc;ller K, et al.Interleukin-1 antagonist anakinra in amyotrophic lateral sclerosis&#x2013;A pilot study. PLoS One. 2015;10(10):e0139684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4596620</ArticleId><ArticleId IdType="pubmed">26444282</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Moore DH, Forshew DA, et al.;WALS Study Group. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: Examining a more efficient trial design. Neurology. 2011;77(10):973&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3171956</ArticleId><ArticleId IdType="pubmed">21813790</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland JM, Moore D, Wang Y, et al.; Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium. Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle Nerve. Feb 2019;59(2):201&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6545236</ArticleId><ArticleId IdType="pubmed">30192007</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al.Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. Sep 3 2020;383(10):919&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Stahl DR, et al.; Uk-Mnd LicalS. Comparison of the King's and MiToS staging systems for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3-4):227&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5425622</ArticleId><ArticleId IdType="pubmed">28054828</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker LA, Schr&#xf6;der CD, van Es MA, Westers P, Visser-Meily JMA, van den Berg LH.. Assessment of the factorial validity and reliability of the ALSFRS-R: A revision of its measurement model. J Neurol. 2017;264(7):1413&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5502060</ArticleId><ArticleId IdType="pubmed">28608303</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F, Mora G, Giordano A, Volanti P, Chio A.. Evidence of multidimensionality in the ALSFRS-R Scale: A critical appraisal on its measurement properties using Rasch analysis. J Neurol Neurosurg Psychiatry. Dec 2013;84(12):1340&#x2013;1345.</Citation><ArticleIdList><ArticleId IdType="pubmed">23516308</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, Bedlack R, Quinn C, et al.Development and validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS). JAMA Neurol. 2020;77(4):480&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6990811</ArticleId><ArticleId IdType="pubmed">31886839</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, Pupillo E, Bonito V, et al.; Italian ALS Study Group. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(5-6):397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">23421600</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, van den Berg LH, Shefner JM, et al.Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): A randomised, double-blind, phase 3 trial. Lancet Neurol. 2013. doi:10.1016/S1474-4422(13)70221-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraete E, Veldink JH, Huisman MH, et al.Lithium lacks effect on survival in amyotrophic lateral sclerosis: A phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry. 2012;83(5):557&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">22378918</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg LH, Sorenson E, Gronseth G, et al.; Airlie House ALS Clinical Trials Guidelines Group. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92(14):e1610&#x2013;e1623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, et al.Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(2):157&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A.. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84(1):130&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et al. CReATe Consortium. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95(1):e59&#x2013;e69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrara M, Sigurdardottir A, Bertolotti A.. Decoding the selectivity of eIF2&#x3b1; holophosphatases and PPP1R15A inhibitors. Nat Struct Mol Biol. 2017;24(9):708&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5591645</ArticleId><ArticleId IdType="pubmed">28759048</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YR, King OD, Shorter J, Gitler AD.. Stress granules as crucibles of ALS pathogenesis. J Cell Biol. 2013;201(3):361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Cabuy E, Caroni P.. A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. Nat Neurosci. 2009;12(5):627&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">19330001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciechanover A, Kwon YT.. Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies. Exp Mol Med. 2015;47:e147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351408</ArticleId><ArticleId IdType="pubmed">25766616</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordlund A, Oliveberg M.. SOD1-associated ALS: A promising system for elucidating the origin of protein-misfolding disease. HFSP J. 2008;2(6):354&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2645584</ArticleId><ArticleId IdType="pubmed">19436494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW.. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009;187(6):761&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Shellikeri S, Keith J, Black SE, Zinman L, Yunusova Y.. Neuropathology of speech network distinguishes bulbar from nonbulbar amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2020;79(3):284&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7036661</ArticleId><ArticleId IdType="pubmed">31951003</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>